Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07112612) titled 'Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer' on Aug. 2.
Study Type: Observational
Primary Sponsor: Anhui Medical University
Condition:
MRD
Prostate Cancer
mHSPC
Recruitment Status: Not recruiting
Date of First Enrollment: September 1, 2025
Target Sample Size: 50
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07112612
Published by HT Digital Content Services with permission from Health Daily Digest....